Timothy Chiang
Stock Analyst at Capital One
(0.19)
# 3,255
Out of 4,479 analysts
6
Total ratings
20%
Success rate
-12.72%
Average return
Main Sectors:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Initiates: Overweight | n/a | $62.64 | - | 1 | Mar 15, 2024 | |
| AKYA Akoya Biosciences | Initiates: Overweight | $19 | $2.18 | +771.56% | 1 | Nov 3, 2022 | |
| PTGX Protagonist Therapeutics | Initiates: Buy | $55 | $34.59 | +59.01% | 2 | Feb 11, 2022 | |
| AMPH Amphastar Pharmaceuticals | Upgrades: Outperform | n/a | $37.58 | - | 1 | Oct 5, 2020 | |
| IDYA IDEAYA Biosciences | Initiates: Outperform | n/a | $33.72 | - | 1 | Sep 1, 2020 |
ANI Pharmaceuticals
Mar 15, 2024
Initiates: Overweight
Price Target: n/a
Current: $62.64
Upside: -
Akoya Biosciences
Nov 3, 2022
Initiates: Overweight
Price Target: $19
Current: $2.18
Upside: +771.56%
Protagonist Therapeutics
Feb 11, 2022
Initiates: Buy
Price Target: $55
Current: $34.59
Upside: +59.01%
Amphastar Pharmaceuticals
Oct 5, 2020
Upgrades: Outperform
Price Target: n/a
Current: $37.58
Upside: -
IDEAYA Biosciences
Sep 1, 2020
Initiates: Outperform
Price Target: n/a
Current: $33.72
Upside: -